Src kinase inhibition restores E-cadherin expression in Dasatinib-sensitive pancreatic cancer cells

Austin R. Dosch, Xizi Dai, Alexander A. Gaidarski, Chanjuan Shi, Jason A. Castellanos, Michael Vansaun, Nipun Merchant, Nagaraj Nagathihalli

Research output: Contribution to journalArticle

Abstract

The Src family of non-receptor tyrosine kinases are frequently activated in pancreatic ductal adenocarcinoma (PDAC), contributing to disease progression through downregulation of E-cadherin and induction of epithelial-to-mesenchymal transition (EMT). The purpose of this study was to examine the efficacy of Src kinase inhibition in restoring E-cadherin levels in PDAC. Immunohistochemical analysis of human PDAC samples showed Src activation is inversely correlated with E-cadherin levels. Protein and mRNA levels of E-cadherin, the gene expression of its various transcriptional repressors (Zeb1, Snail, Slug, LEF-1, TWIST), and changes in sub-cellular localization of E-cadherin/β-catenin in PDAC cells were characterized in response to treatment with the Src inhibitor, dasatinib (DST). DST repressed Slug mRNA expression, promoted E-cadherin transcription, and increased total and membranous E-cadherin/β-catenin levels in drug-sensitive PDAC cells (BxPC3 and SW1990), however no change was observed in drug-resistant PANC1 cells. BxPC3, PANC1, and MiaPaCa-2 flank tumor xenografts were treated with DST to examine changes in E-cadherin levels in vivo. Although DST inhibited Src phosphorylation in all xenograft models, E-cadherin levels were only restored in BxPC3 xenograft tumors. These results suggest that Src kinase inhibition reverses EMT in drug-sensitive PDAC cells through Slug-mediated repression of E-cadherin and identifies E-cadherin as potential biomarker for determining response to DST treatment.

Original languageEnglish (US)
Pages (from-to)1056-1069
Number of pages14
JournalOncotarget
Volume10
Issue number10
StatePublished - Feb 1 2019

Fingerprint

src-Family Kinases
Cadherins
Pancreatic Neoplasms
Adenocarcinoma
Gastropoda
Heterografts
Catenins
Epithelial-Mesenchymal Transition
Dasatinib
Pharmaceutical Preparations
Messenger RNA
Protein-Tyrosine Kinases
Disease Progression
Neoplasms
Down-Regulation
Biomarkers
Phosphorylation
Gene Expression

Keywords

  • Dasatinib
  • E-cadherin
  • Epithelial-to-mesenchymal transition (EMT)
  • Pancreatic ductal adenocarcinoma
  • SRC kinase

ASJC Scopus subject areas

  • Oncology

Cite this

Dosch, A. R., Dai, X., Gaidarski, A. A., Shi, C., Castellanos, J. A., Vansaun, M., ... Nagathihalli, N. (2019). Src kinase inhibition restores E-cadherin expression in Dasatinib-sensitive pancreatic cancer cells. Oncotarget, 10(10), 1056-1069.

Src kinase inhibition restores E-cadherin expression in Dasatinib-sensitive pancreatic cancer cells. / Dosch, Austin R.; Dai, Xizi; Gaidarski, Alexander A.; Shi, Chanjuan; Castellanos, Jason A.; Vansaun, Michael; Merchant, Nipun; Nagathihalli, Nagaraj.

In: Oncotarget, Vol. 10, No. 10, 01.02.2019, p. 1056-1069.

Research output: Contribution to journalArticle

Dosch AR, Dai X, Gaidarski AA, Shi C, Castellanos JA, Vansaun M et al. Src kinase inhibition restores E-cadherin expression in Dasatinib-sensitive pancreatic cancer cells. Oncotarget. 2019 Feb 1;10(10):1056-1069.
Dosch, Austin R. ; Dai, Xizi ; Gaidarski, Alexander A. ; Shi, Chanjuan ; Castellanos, Jason A. ; Vansaun, Michael ; Merchant, Nipun ; Nagathihalli, Nagaraj. / Src kinase inhibition restores E-cadherin expression in Dasatinib-sensitive pancreatic cancer cells. In: Oncotarget. 2019 ; Vol. 10, No. 10. pp. 1056-1069.
@article{88e4b4eede2c4e278b4066f8e81c5c86,
title = "Src kinase inhibition restores E-cadherin expression in Dasatinib-sensitive pancreatic cancer cells",
abstract = "The Src family of non-receptor tyrosine kinases are frequently activated in pancreatic ductal adenocarcinoma (PDAC), contributing to disease progression through downregulation of E-cadherin and induction of epithelial-to-mesenchymal transition (EMT). The purpose of this study was to examine the efficacy of Src kinase inhibition in restoring E-cadherin levels in PDAC. Immunohistochemical analysis of human PDAC samples showed Src activation is inversely correlated with E-cadherin levels. Protein and mRNA levels of E-cadherin, the gene expression of its various transcriptional repressors (Zeb1, Snail, Slug, LEF-1, TWIST), and changes in sub-cellular localization of E-cadherin/β-catenin in PDAC cells were characterized in response to treatment with the Src inhibitor, dasatinib (DST). DST repressed Slug mRNA expression, promoted E-cadherin transcription, and increased total and membranous E-cadherin/β-catenin levels in drug-sensitive PDAC cells (BxPC3 and SW1990), however no change was observed in drug-resistant PANC1 cells. BxPC3, PANC1, and MiaPaCa-2 flank tumor xenografts were treated with DST to examine changes in E-cadherin levels in vivo. Although DST inhibited Src phosphorylation in all xenograft models, E-cadherin levels were only restored in BxPC3 xenograft tumors. These results suggest that Src kinase inhibition reverses EMT in drug-sensitive PDAC cells through Slug-mediated repression of E-cadherin and identifies E-cadherin as potential biomarker for determining response to DST treatment.",
keywords = "Dasatinib, E-cadherin, Epithelial-to-mesenchymal transition (EMT), Pancreatic ductal adenocarcinoma, SRC kinase",
author = "Dosch, {Austin R.} and Xizi Dai and Gaidarski, {Alexander A.} and Chanjuan Shi and Castellanos, {Jason A.} and Michael Vansaun and Nipun Merchant and Nagaraj Nagathihalli",
year = "2019",
month = "2",
day = "1",
language = "English (US)",
volume = "10",
pages = "1056--1069",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "10",

}

TY - JOUR

T1 - Src kinase inhibition restores E-cadherin expression in Dasatinib-sensitive pancreatic cancer cells

AU - Dosch, Austin R.

AU - Dai, Xizi

AU - Gaidarski, Alexander A.

AU - Shi, Chanjuan

AU - Castellanos, Jason A.

AU - Vansaun, Michael

AU - Merchant, Nipun

AU - Nagathihalli, Nagaraj

PY - 2019/2/1

Y1 - 2019/2/1

N2 - The Src family of non-receptor tyrosine kinases are frequently activated in pancreatic ductal adenocarcinoma (PDAC), contributing to disease progression through downregulation of E-cadherin and induction of epithelial-to-mesenchymal transition (EMT). The purpose of this study was to examine the efficacy of Src kinase inhibition in restoring E-cadherin levels in PDAC. Immunohistochemical analysis of human PDAC samples showed Src activation is inversely correlated with E-cadherin levels. Protein and mRNA levels of E-cadherin, the gene expression of its various transcriptional repressors (Zeb1, Snail, Slug, LEF-1, TWIST), and changes in sub-cellular localization of E-cadherin/β-catenin in PDAC cells were characterized in response to treatment with the Src inhibitor, dasatinib (DST). DST repressed Slug mRNA expression, promoted E-cadherin transcription, and increased total and membranous E-cadherin/β-catenin levels in drug-sensitive PDAC cells (BxPC3 and SW1990), however no change was observed in drug-resistant PANC1 cells. BxPC3, PANC1, and MiaPaCa-2 flank tumor xenografts were treated with DST to examine changes in E-cadherin levels in vivo. Although DST inhibited Src phosphorylation in all xenograft models, E-cadherin levels were only restored in BxPC3 xenograft tumors. These results suggest that Src kinase inhibition reverses EMT in drug-sensitive PDAC cells through Slug-mediated repression of E-cadherin and identifies E-cadherin as potential biomarker for determining response to DST treatment.

AB - The Src family of non-receptor tyrosine kinases are frequently activated in pancreatic ductal adenocarcinoma (PDAC), contributing to disease progression through downregulation of E-cadherin and induction of epithelial-to-mesenchymal transition (EMT). The purpose of this study was to examine the efficacy of Src kinase inhibition in restoring E-cadherin levels in PDAC. Immunohistochemical analysis of human PDAC samples showed Src activation is inversely correlated with E-cadherin levels. Protein and mRNA levels of E-cadherin, the gene expression of its various transcriptional repressors (Zeb1, Snail, Slug, LEF-1, TWIST), and changes in sub-cellular localization of E-cadherin/β-catenin in PDAC cells were characterized in response to treatment with the Src inhibitor, dasatinib (DST). DST repressed Slug mRNA expression, promoted E-cadherin transcription, and increased total and membranous E-cadherin/β-catenin levels in drug-sensitive PDAC cells (BxPC3 and SW1990), however no change was observed in drug-resistant PANC1 cells. BxPC3, PANC1, and MiaPaCa-2 flank tumor xenografts were treated with DST to examine changes in E-cadherin levels in vivo. Although DST inhibited Src phosphorylation in all xenograft models, E-cadherin levels were only restored in BxPC3 xenograft tumors. These results suggest that Src kinase inhibition reverses EMT in drug-sensitive PDAC cells through Slug-mediated repression of E-cadherin and identifies E-cadherin as potential biomarker for determining response to DST treatment.

KW - Dasatinib

KW - E-cadherin

KW - Epithelial-to-mesenchymal transition (EMT)

KW - Pancreatic ductal adenocarcinoma

KW - SRC kinase

UR - http://www.scopus.com/inward/record.url?scp=85061036159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061036159&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85061036159

VL - 10

SP - 1056

EP - 1069

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 10

ER -